RA Capital, InCube lead $30m series-B for WhiteSwell

The fresh capital will fund product development and medical studies of the company's treatment for acute decompensated heart failure (ADHF).

As part of the deal, WhiteSwell has appointed former Neuravi CEO Eamon Brady and former Neuravi CFO Seán Mac Réamoinn in the same roles.

Company
Founded in Israel in 2014 and now headquartered in Galway, WhiteSwell is developing a minimally invasive catheter-based treatment for ADHF. The treatment is intended to remove excess interstitial fluid in patients with ADHF more efficiently by bolstering the natural fluid removal process of the lymphatic system.

People
RA Capital – Andrew Levin (managing director).
InCube Ventures – Andrew Farquharson (co-founder, managing director).
WhiteSwell – Yaacov Nitzan (founder, chief technology officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Ireland
• Venture